Search research articles
Contact Us
Filters
Showing results (141-150 of 163) with videos related to
Page
of 17
Sort By:
Immunity
|
September 14, 2022
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Immunity
|
December 16, 2018
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2026
Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19
Richard Cathomas, Ulf Petrausch, Stefanie Hayoz, et al.
The Journal of Clinical Investigation
|
August 22, 2018
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Michal A Stanczak, Shoib S Siddiqui, Marcel P Trefny, et al.
Oncoimmunology
|
July 29, 2016
Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma
Hans A Schlößer, Uta Drebber, Michael Kloth, et al.
Cancer Immunology Research
|
April 17, 2024
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
David König, Michael T Sandholzer, Sarp Uzun, et al.
Science Immunology
|
May 10, 2024
Nucleobase adducts bind MR1 and stimulate MR1-restricted T cells
Alessandro Vacchini, Andrew Chancellor, Qinmei Yang, et al.
Immunity
|
June 14, 2023
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses
Felix Bayerl, Philippa Meiser, Sainitin Donakonda, et al.
Oncotarget
|
October 21, 2017
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition
Gongda Xue, Reto Kohler, Fengyuan Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 12, 2021
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
Sacha I Rothschild, Alfred Zippelius, Eric I Eboulet, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 163) with videos related to
Sort By:
Page
of 17
Immunity
|
September 14, 2022
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Immunity
|
December 16, 2018
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2026
Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19
Richard Cathomas, Ulf Petrausch, Stefanie Hayoz, et al.
The Journal of Clinical Investigation
|
August 22, 2018
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Michal A Stanczak, Shoib S Siddiqui, Marcel P Trefny, et al.
Oncoimmunology
|
July 29, 2016
Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma
Hans A Schlößer, Uta Drebber, Michael Kloth, et al.
Cancer Immunology Research
|
April 17, 2024
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
David König, Michael T Sandholzer, Sarp Uzun, et al.
Science Immunology
|
May 10, 2024
Nucleobase adducts bind MR1 and stimulate MR1-restricted T cells
Alessandro Vacchini, Andrew Chancellor, Qinmei Yang, et al.
Immunity
|
June 14, 2023
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses
Felix Bayerl, Philippa Meiser, Sainitin Donakonda, et al.
Oncotarget
|
October 21, 2017
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition
Gongda Xue, Reto Kohler, Fengyuan Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 12, 2021
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
Sacha I Rothschild, Alfred Zippelius, Eric I Eboulet, et al.
Page
of 17